KT 1002
Alternative Names: BC-1261; KT-1002Latest Information Update: 28 Aug 2023
At a glance
- Originator United States Department of Veterans Affairs; University of Pittsburgh
- Developer Koutif Therapeutics
- Class Anti-inflammatories; Antibronchitics; Antirheumatics; Small molecules
- Mechanism of Action Fbx3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute lung injury; Bronchiolitis obliterans; Chronic obstructive pulmonary disease; Crohn's disease; Inflammatory bowel diseases; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Bronchiolitis Obliterans in USA (PO)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Crohn's-disease in USA (PO)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases in USA (PO)